

- (ii) "Avoid contact with the eyes."
- (iii) "If you or your partner develop a rash or irritation, such as burning or itching, discontinue use. If symptoms persist, consult a doctor."

(2) [Reserved]

(d) *Directions*. The labeling of the product contains the following information under the heading "Directions":

(1) *For products containing any ingredient identified in §348.10(a)*—(i) *For products containing benzocaine identified in §348.10(a)(1)*. "Apply a small amount to head and shaft of penis before intercourse, or use as directed by a doctor. Wash product off after intercourse."

(ii) *For products containing lidocaine identified in §348.10(a)(2)*. "Apply 3 or more sprays, not to exceed 10, to head and shaft of penis before intercourse, or use as directed by a doctor. Wash product off after intercourse."

(2) [Reserved]

(e) The word "physician" may be substituted for the word "doctor" in any of the labeling statements in this section.

PART 349—OPHTHALMIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE

Subpart A—General Provisions

Sec.

349.1 Scope.

349.3 Definitions.

Subpart B—Active Ingredients

349.10 Ophthalmic astringent.

349.12 Ophthalmic demulcents.

349.14 Ophthalmic emollients.

349.16 Ophthalmic hypertonicity agent.

349.18 Ophthalmic vasoconstrictors.

349.20 Eyewashes.

349.30 Permitted combinations of active ingredients.

Subpart C—Labeling

349.50 Labeling of ophthalmic drug products.

349.55 Labeling of ophthalmic astringent drug products.

349.60 Labeling of ophthalmic demulcent drug products.

349.65 Labeling of ophthalmic emollient drug products.

349.70 Labeling of ophthalmic hypertonicity drug products.

349.75 Labeling of ophthalmic vasoconstrictor drug products.

349.78 Labeling of eyewash drug products.

349.79 Labeling of permitted combinations of active ingredients.

349.80 Professional labeling.

AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371.

SOURCE: 53 FR 7090, Mar. 4, 1988, unless otherwise noted.

Subpart A—General Provisions

§349.1 Scope.

(a) An over-the-counter ophthalmic drug product in a form suitable for topical administration is generally recognized as safe and effective and is not misbranded if it meets each of the conditions in this part and each of the general conditions established in §330.1.

(b) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.

§349.3 Definitions.

As used in this part:

(a) *Ophthalmic drug product*. A drug product, which should be sterile in accordance with §200.50, to be applied to the eyelid or instilled in the eye.

(b) *Astringent*. A locally acting pharmacologic agent which, by precipitating protein, helps to clear mucus from the outer surface of the eye.

(c) *Buffering agent*. A substance which stabilizes the pH of solutions against changes produced by introduction of acids or bases from such sources as drugs, body fluids, tears, etc.

(d) *Demulcent*. An agent, usually a water-soluble polymer, which is applied topically to the eye to protect and lubricate mucous membrane surfaces and relieve dryness and irritation.

(e) *Emollient*. An agent, usually a fat or oil, which is applied locally to eyelids to protect or soften tissues and to prevent drying and cracking.

(f) *Eyewash, eye lotion, irrigating solution*. A sterile aqueous solution intended for washing, bathing, or flushing the eye.

(g) *Hypertonicity agent*. An agent which exerts an osmotic gradient greater than that present in body tissues and fluids, so that water is drawn